ORIC: רווח נקי למניה ב-12 החודשים האחרונים oricpharma.com
ORIC Pharmaceuticals operates as a virtual biopharma, fully outsourcing synthesis and clinical trials to external contractors. The company's rolling annual profit per share illustrates revenue dynamics, where -1.35 represents the current level of the metric. The business focuses on combating drug-resistant tumors. Development relies on venture capital and close partnerships with industry behemoths to create combination therapies.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_ORIC_-_ORIC-Pharmaceuticals_-_Earnings-per-share-for-the-last-four-quarters "ORIC Pharma - רווח נקי למניה (EPS TTM) ORIC (תקופה 04.07.2022 - 10.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת ORIC Pharmaceuticals
To isolate the fundamental stability of ORIC Pharmaceuticals (ORIC) from market noise, net earnings per share is utilized, which distributes total income across all securities to determine the real return on each share of the business. An analysis of the rolling year earnings per share confirms the financial efficiency of investments in targeted oncology therapy and the highly qualified staff of biologists developing breakthrough treatments.
